Physician profile
Christopher R Spencer
NPI 1568775567
$70,495.55
in general payments reported to CMS, 2019-2025
40 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $73.94 · 2021: $137 · 2022: $31K · 2023: $37K · 2024: $417 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,250.00 |
| Food and Beverage | $1,141.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $68,523.93 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $248.57 | 2019-2025 | |
| Janssen Biotech, INC. | $228.21 | 2019-2025 | Carvykti, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $123.24 | 2023-2025 | Injectafer, Enhertu, Datroway |
| Astrazeneca Pharmaceuticals Lp | $101.16 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Jazz Pharmaceuticals INC. | $80.69 | 2021-2025 | |
| Eisai INC. | $80.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $77.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $75.09 | 2021-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $71.75 | 2019-2025 | |
| Exelixis INC. | $61.10 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $54.95 | 2019-2025 | |
| Mirati Therapeutics, INC. | $51.21 | 2023-2024 | Krazati |
| Incyte Corporation | $50.45 | 2024-2025 | Monjuvi, Pemazyre, Zynyz |
| Regeneron Healthcare Solutions, INC. | $49.44 | 2024-2025 | Libtayo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.